Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW906 injection in primary hypertension (phase II, randomized, double-blind, placebo-controlled)
CTR20254537Phase 2Active
- Sponsor
- Gowell
- Start
- Nov 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in essential hypertension comparing GW906 injection with Placebo injection (2 arms). Started Nov 2025; status: active.
02
Drugs
GW906
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20254537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254537.